Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

Research output: Chapter in Book/Report/Conference proceedingBook chapter

Abstract

Fluid biomarkers, including cerebrospinal fluid (CSF) biomarkers and blood-based biomarkers, may reflect different pathological processes in Alzheimer’s disease (AD) and frontotemporal dementia (FTD). The most used biomarkers are CSF β-amyloid42, total tau, phosphorylated tau, and neurofilament light, which have been studied for diagnosis, prognosis, and treatment follow-up and in relation to genetics and neuroimaging. These biomarkers are now increasingly used in research, drug development, and clinical settings to increase our understanding of AD and FTD and to improve patient management. Recent progress in stable, automated assays for CSF biomarkers and ultrasensitive assays for blood-based biomarkers and the incorporation of fluid biomarkers in clinical practice and in clinical trials have accelerated the field. Key issues for further research include more extensive studies of the earliest stages of neurodegenerative diseases, better biomarkers for distinct proteinopathies, and the creation of universally accepted guidelines specifying the role of fluid biomarkers in relation to clinical measures and neuroimaging findings.

Details

Authors
Organisations
External organisations
  • Skåne University Hospital
  • Sahlgrenska Academy
  • Sahlgrenska University Hospital
  • University College London
  • UK Dementia Research Institute
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Neurology

Keywords

  • Alzheimer, Amyloid, Biomarker, Frontotemporal lobe dementia, Neurofilament, Tau
Original languageEnglish
Title of host publicationNeurodegeneratIve Diseases
Subtitle of host publicationClinical Aspects, Molecular Genetics and Biomarkers
PublisherSpringer
Pages221-252
Number of pages32
ISBN (Electronic)9783319729381
ISBN (Print)9783319729374
Publication statusPublished - 2018 Jan 1
Publication categoryResearch
Peer-reviewedYes